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INTRODUCTION: Nephrogenic diabetes insipidus is characterized by a lack of response in the distal nephron to the antidiuretic 
hormone arginine vasopressin. Manifestations include polyuria, polydipsia, hyposthenuria, recurrent episodes of dehydration and fever 
and growth failure. Most cases are caused by mutations in the AVPR2 gene. The mutant receptors are trapped intracellularly. 
METHOD: We studied five boys using clinical, laboratory and molecular data. The mean age at diagnosis was 14.6 months (range 
6 to 24) and 12.2 years (7.8 to 19) after the follow-up period. The mean period of follow-up was 132.2 ± 50.9 months. 
RESULTS: The geometric means of the z-scores of weight and stature were -4.5 and -3.6, respectively, at diagnosis. At the last 
medical appointment, the z-scores of weight and stature were -0.3 and -0.9, respectively. Three patients were diagnosed with ure-
terohydronephrosis and exhibited increased post-void urine volume. Mutations in the AVPR2 gene were found in all patients, and 
the carrier status was confirmed in four of five cases. Two unrelated children presented identical mutations (S167L) in arginine 
vasopressin R2. Two of the patients had a mutation that has already been described in other Brazilian families (R337X), and one 
patient showed a de novo mutation (Y128D) in arginine vasopressin R2, since his mother’s molecular analysis was normal. The 
recurrence risk for this family was significantly reduced.
CONCLUSION: This study reports the clinical and laboratory characterization of Nephrogenic diabetes insipidus and reiterates 
the importance of the genetic basis that underlies the disease diagnosis and genetic counseling. 
KEYWORDS: Nephrogenic insipidus diabetes; Children; Molecular study; Pharmacological chaperones; Hydrochlorothiazide.
INTRODUCTION
Nephrogenic diabetes insipidus (NDI) is characterized 
by a lack of response of the distal nephron to the antidiuretic 
hormone AVP (arginine vasopressin). As a consequence, the 
kidneys fails to concentrate urine.1,2 NDI, which can be either 
inherited or acquired, is clinically indistinguishable from the 
central diabetes insipidus. The diagnosis of NDI is confirmed 
by the water deprivation test under 1-desamino-8-D-arginine 
vasopressin (DDAVP) that demonstrates a lack of increase 
of urine osmolality and no reduction in urine volume or free 
water clearance.3 
The hereditary form of NDI is a rare condition that 
develops soon after birth and can present as a failure to thrive 
accompanied by mental retardation, especially if diagnosis 
and appropriate treatment are delayed.1,2 The most common 
manifestations are polyuria, polydipsia and hyposthenuria 
with recurrent episodes of dehydration and fever, along with 
poor nutritional intake and growth failure.
The antidiuretic hormone 8-arginine vasopressin 
(AVP)3,4 binds to a specific receptor, the vasopressin V2 
receptor (AVPR2), located on the basolateral membrane 
of the collecting duct cells.2 A cascade of reactions then 
takes place: the receptor-linked protein G activation, adenyl 
cyclase activation, cyclic AMP (cAMP) production and 
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protein kinase stimulation. Finally, there is an increase in 
the exocytic insertion of specific water channels, namely 
aquaporin 2 or AQP2, into the luminal membrane that 
ultimately results in increased water permeability.2,4,5 In 
summary, AVPR2 and AQP2 are critical compounds for the 
transepithelial water permeability of the principal cells of the 
collecting ducts because a loss of function of either of these 
proteins will result in NDI (Figure 1).
In the majority of cases (approximately 90%),1 the defect 
is secondary to a mutation in the AVPR2 gene,6 resulting in 
an X-linked recessive inheritance pattern. Thus, this form 
of NDI occurs mainly in males, although there have been 
reports of heterozygote females with variable manifestations 
of the disease.7 The AVPR2 gene is located in chromosome 
region Xq28 and features three exons and two small introns. 
The sequence of the complementary DNA predicts a 
polypeptide of 371 amino acids with seven transmembrane, 
four extracellular, and four cytoplasmic domains.3,8 To 
date, approximately 190 mutations have been described 
worldwide.9 
The autosomal forms of inheritance, which are much 
less frequent, are due to mutations in the AQP2 gene.3,6 
The human AQP2 gene is located in chromosome region 
12q13, features four exons and three introns, and codes for 
a polypeptide of 271 amino acids.10,11
Most missense AVPR2 mutations lead to receptors that 
are trapped intracellularly; a few mutant receptors reach 
the cell surface but are unable to bind AVP or to properly 
trigger an intracellular cyclic adenosine monophosphate 
signal3. Similarly, most AQP2 mutant proteins are also 
misrouted.11 As numerous studies have revealed that 
endoplasmic reticulum (ER)-retained mutant proteins are 
often functional, research over the past decade has focused 
on identifying compounds that can rescue the cell surface 
expression of such proteins. In this respect, the vasopressin 
type 2 receptor (V2R) is the prototypical protein, as it was 
the first receptor for which the exciting discovery was 
made that cell-permeable antagonists (CPAn, known as 
“pharmacochaperones”) can promote cell surface trafficking 
of its ER-retained mutants.12 Studies with these antagonists 
have been performed in the context of NDI.13
Since there have been meaningful advances with the 
development of pharmacological chaperones, Fujiwara and 
Bichet10 suggest that all families with NDI should undergo 
molecular analysis because of the availability of immediate 
clinical and early therapeutic measures, and the possibility 
of preventing recurrent dehydration episodes and their 
consequences. 
This study was performed to report the clinical, 
laboratory and genetic characteristics of patients with NDI, 
from the Pediatric Nephrology Unit of the Instituto da 
Criança – HCFMUSP.
MATERIAL AND METHODS
Clinical and laboratory data from patients with NDI, 
followed in the outpatient Pediatric Nephrology Unit of the 
Instituto da Criança – HCFMUSP, were recorded in medical 
records at the time of diagnosis and at the last medical 
appointment. The data consisted of demographic factors 
(age, gender, and race); anthropometric measurements 
(weight and height); clinical manifestations and physical 
exam at diagnosis, including hydration status and irritability; 
familial history; and the degree of compromise of extra-renal 
organs. In the follow-up period, we observed the growth 
parameters (weight and height) and the neurological status 
(developmental milestones, neurological sequelae).
The following blood tests were performed: sodium, 
potassium, chloride, urea, creatinine, plasma osmolality and 
venous blood gas. In addition, urine exams recorded pH, 
density, osmolality, sodium, potassium, chloride and the 
presence of proteinuria. An annual renal ultrasonography 
was also included, mainly to evaluate urinary tract dilatation 
and post-void urine volume. 
The molecular analysis was performed at the Molecular 
Genetics Laboratory – Faculdade de Medicina da 
Universidade Federal de Minas Gerais (UFMG), Brazil, 
using PCR amplification with specific primers followed by 
direct sequencing of the AVPR2 gene using ABI 310 and ABI 
3130 Genetic Analyzers (Applied Biosystems, Foster City, 
CA) as previously described.9,14 Peripheral blood samples 
from the patient and the parents were collected, and genomic 
DNA were extracted for analysis using the GenomicPrep 
Figure 1 - Illustrative model of the arginine vasopressin (AVP) action in 
a collecting tubular cell, showing the AVP binding to V2 receptor (V2R), 
causing the deflagration of a cascade of events. The final result is the mi-
gration of water channels (AQP2) to the luminal surface with consequent 
water reabsorption
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Blood DNA Isolation kit (GE HealthCare, Piscataway, NJ) 
following the manufacturer’s recommended protocol. All 
PCR products were sequenced in both forward and reverse, 
in duplicate.
Whenever possible, we calculated the geometric means 
and standard deviations, as well as the z-scores for stature 
and weight.
RESULTS
Five boys with NDI were studied. The age at diagnosis 
ranged from 6 to 24 months (mean = 14.6 months) and 
from 7.8 to 19 years (mean = 12.2 years) after the follow-
up period. The mean period of follow-up was 132.2 ± 50.9 
months. 
All patients presented with failure to thrive, fever and 
dehydration episodes, polyuria and polydipsia. In addition, 
they had each been admitted to the hospital several times 
prior to diagnosis. In all cases, NDI was confirmed using 
the water deprivation test which showed a lack of response 
to DDAVP.
Table 1 shows the gender, age at diagnosis and at last 
appointment, and z-scores for weight and height at diagnosis 
and at the end of the study for each patient. The geometric 
mean of the z-score was -4.5 for weight and -3.6 for stature 
at diagnosis. At the last visit, the z-score was -0.3 for weight 
and -0.9 for stature. Table 2 shows the laboratory results 
at diagnosis and at the last appointment. The glomerular 
filtration rate (GFR) was estimated using the Schwartz 
equation. Table 3 lists the neurological findings of the five 
patients studied.
Among all five patients, three were diagnosed with 
ureterohydronephrosis and increased post-void urine volume. 
Such finding was more common in those patients with a 
longer disease profile.
The chosen therapeutic approach in all cases included an 
increase in water intake and a low-salt, normal protein diet 
(2 – 2.5 mg of protein per kilogram daily). All patients were 
administered hydrochlorothiazide (1-2 mg/kg/day); three 
patients needed potassium replacement for hypokalemia 
during the treatment, and only one patient (patient 2) used 
a non-steroidal anti-inflammatory drug (Celecoxib®) for 15 
days in an effort to reduce the enormous urinary volume. 
However, this patient subsequently developed arterial 
hypertension, which was controlled after use of this drug 
Table 1 - Summarized data from the five NDI patients
Patient Gender Age at diagnosis 
(months)
Age at final visit 
(years)
Z-score of 
initial weight
Z-score of final 
visit weight
Z-score of 
initial stature
Z-score of final 
visit stature
1 Male 24 15 -4. 73 0.63 -3. 73 -0.58
2 Male 20 19 -3. 61 -0. 08 -3. 50 -0.20
3 Male 15 7.8 -3. 56 -0. 37 -2. 97 -1.44
4 Male 6 10. 4 -5. 55 -1. 81 -4. 54 -2.43
5 Male 8 9 -5. 48 -0. 10 -3. 33 0.06
Table 2 - Laboratory findings
Patient Serum creatinine (mg/dL) Serum urea (mg/dL) creatinine clearance (ml/min/1.73m2bs)
at presentation at final visit at presentation at final visit at presentation at final visit
1 0.8 0.95 41 22 43.6 126.7
2 0.7 1.2 38 30 48.2 99.1
3 0.26 0.52 13.5 31 121.1 108.1
4 0.53 0.39 41 10 49.25 150.5
5 0.6 0.36 49 17 47.2 160.0
BS = body surface
Table 3 - Neurological findings
Patient Neurological abnormalities
1 Cognitive compromise
2 None
3 None
4 None
5 Seizures
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was discontinued. Patient 5 presented a severe hemodynamic 
compromise with hypovolemic shock after a fasting period 
that was necessary for an endoscopic exam. After this 
episode, he developed seizures and has since been prescribed 
sodium valproate.
Molecular Analysis
We examined the genomic DNA extracted from 
peripheral blood leukocytes. First, all patients were tested 
for mutations in the AVPR2 gene. Direct sequencing was 
performed, and mutations were found in all patients. The 
results are shown in Table 4. In patients with mutations in 
AVPR2, their mothers were tested, and carrier status was 
confirmed in 4 of 5 cases.
Two unrelated children presented identical mutations 
(S167L) in the AVPR2 gene. Two patients had a mutation 
that has been described elsewhere in other Brazilian patients 
(R337X). The molecular analysis results are summarized in 
Table 4.
DISCUSSION
Hereditary NDI is a genetic condition characterized 
by an insensitivity of tubular cells to AVP despite normal 
or increased levels of this hormone. It is a severe disease, 
with manifestations in early infancy - including polyuria, 
polydipsia, hyposthenuria and hypernatremic dehydration. 
This disease can be life-threatening and is aggravated by 
feeding the child infant formula instead of breast-feeding 
due to its increased sodium content. The clinical suspicion 
is confirmed by the specific tests cited above.
We have observed improved growth and weight gain with 
adequate therapy, such as an increased water intake rate, 
under a low-salt diet in the context of hydrochlorothiazide 
administration, similar to that reported in Lejarraga et al.15 
Treatment with thiazides, which promote decreased free 
water clearance by increasing both sodium reabsorption 
and water retention, is also thought to increase the luminal 
expression of AQP2 and distal renal sodium transporters.16 
The use of non-steroidal anti-inflammatory drugs reduces 
the urinary volume. However, a possible side-effect is the 
reduction of the glomerular filtration rate, leading to chronic 
renal failure with low clearance over both medium- and 
long-term intervals. Patient 2 underwent this therapeutic 
option with successful reduction in the urinary volume, 
though he developed arterial hypertension which required 
discontinuation of the drug.
Adherence to treatment is essential for clinical recovery, 
especially in the X-linked cases of NDI. The NDI cases 
caused by AQP2 mutations are responsible for a more 
severe clinical picture and poor response to treatment. 
Finally, urinary tract dilatation and neurogenic bladder are 
not uncommon manifestations. Preventive techniques, such 
as frequent voiding and nocturnal catheterization, might be 
considered as options to avoid these complications.
Intracellular retention of a functional vasopressin V2 
receptor (V2R) mutant is a major cause of congenital NDI, 
and the rescue of V2R mutants by nonpeptide antagonists 
may restore their basolateral membrane localization and 
function.3 The method by which CPAns (cell permeable 
antagonists) rescue V2R mutants has been the subject of 
several studies.12 At present, however, it is not completely 
clear which features of CPAn are important to give the best 
functional rescue of V2R mutants under such conditions. 
A crucial aspect necessary for functional rescue besides 
rescued cell surface expression of the mutant is displacement 
of the V2R-bound antagonist by AVP to generate a cAMP 
response.13
Binding of CPAns to a mutant receptor can reverse the 
distorting effect of the mutation and thus aid in protein 
folding. Following rescue to the cell surface, however, most 
of the V2R mutants are able to bind AVP and consequently 
elicit a cAMP response. Functional rescue can only be 
achieved if the pharmacological chaperone is displaced by an 
agonist, thereby allowing receptor activation and induction 
of the signaling cascade.13 
Therefore, to be of clinical value, the functional rescue 
of V2R mutants should occur at low concentrations of 
antagonists and AVP; in addition, the restoration of function 
should last as long as possible.
Recent studies with these antagonists have shown 
that the functional rescue of mutant V2Rs at clinically 
practical concentrations is most effective with high-affinity 
antagonists. Morello et al. showed that pretreatment with the 
high-affinity cell-permeable V2R antagonist SR121463A 
restored cell surface expression in 8 of 15 ER-retained 
V2R mutants that were subsequently activated by AVP 
(i.e., functional rescue).12 Recently, Robben et al. have 
demonstrated that the antagonists OPC31260 and OPC41061 
promote a functional rescue of the V2R mutant. OPC31260 
is currently being tested as a treatment for polycystic 
Table 4 - Molecular results
Patient Gene Mutation Parents
1 AVPR2 c.500C>T (S167L) Heterozygous mother 
2 AVRP2 c.500C>T (S167L) Heterozygous mother 
3 AVPR2 c.1009C>T (R337X) Heterozygous mother 
4 AVPR2 c.382T>G (Y128D) No mutation found
5 AVPR2 c.1009C>T (R337X) Heterozygous mother
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kidney disease,17 while OPC41601 is under trial to treat 
hyponatremia and congestive heart failure in humans.18 Since 
negative side effects have not been reported in these studies, 
OPC31260 and OPC41061 represent safe and promising 
candidates to treat NDI in patients with V2R mutants.19 
Certainly more studies are necessary to confirm their efficacy 
and lack of toxicity. In conclusion, the molecular defect 
characterization seems to be essential to best select potential 
patients to be treated with these pharmacochaperones.
In this study we detected two families (those of patients 
1 and 2), apparently unrelated, who exhibited the same 
mutation in AVPR2 (S167L), as well as two other patients 
who presented a mutation that had been reported elsewhere 
in Brazil (R337X).9 This may raise the possibility of a 
founder effect in some Brazilian cases.
In addition, to illustrate the importance of molecular 
analysis in the context of genetic counseling, four of our five 
patients with AVPR2 mutations inherited the disease from 
their mothers. Only patient 4 showed a de novo mutation 
(Y128D) in AVPR2, since his mother’s molecular analysis 
data was normal. 
This study reported the clinical and laboratory 
characterization of NDI and emphasizes the importance 
of genetic investigations as a basis of disease diagnosis. 
Our work reiterates the need for genetic counseling for the 
affected families.
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